Baird Capital

Baird Capital is a private equity and venture capital firm that specializes in making investments across various sectors, including healthcare, technology-enabled services, industrial solutions, and financial technology. Founded in 1989 and headquartered in Chicago, with additional offices in London and Asia, Baird Capital targets early to growth stage companies, focusing on those with strong management teams and innovative products. The firm typically invests between $1 million and $15 million, emphasizing control in its portfolio. In healthcare, Baird Capital invests in provider and payer solutions, medical devices, and life sciences, while in technology, it focuses on human capital services, financial technology, and marketing solutions. The firm operates globally, with a particular interest in the United States, Europe, and Asia, leveraging its sector expertise and extensive network to drive value in its investments.

Daniel Almon

Principal

Wolfgang Alvano

Managing Director

Robert Andrews

Managing Director, Investment Banking

Joanna Arras

Partner

Jubril Ayanbunmi

Investment Manager

Martin Beck

Partner

Alfredo Bequillard

Managing Director, Capital Advisory

Timothy Byrne

CIO and Managing Director

Thomas Coburn

Director and Global Industrial Group Member

Mark Donnelly

Partner

Aidan Elliott

Investment Manager

Danielle Farmer

Investment Banking, Financial Sponsors Group - Vice President

Mike Fell

Managing Director

Andrew Ferguson

Partner

Jonathan Fitzsimmons

Managing Director, Investment Banking

Robert Foster

Managing Director, Global Consumer Investment Banking

David Fraser

Operating Partner

Alan Fredian

Vice President

Thomas Glynn

Senior Vice President, Private Wealth Management

Alexandra Goldman

Associate

David Gregorka

Venture Partner, Healthcare

Matt Gura

Senior Associate

Dennis Hall

Partner and Global Head of Portfolio Operations

Michael Holgate

Partner, Healthcare and Technology Enabled Services

Gina Kim

Vice President, Knowledge Services and Market Data

Louise Kingston

Director

Anjan Krishna

Associate

Jon Langenfeld

Managing Director, Head of Global Equities and Director of Equity Research

Michael Liang

Partner, US Venture Capital - Healthcare

Michael Magluilo

Managing Director, Technology and Services Group

Timothy Mathison

Vice President

Terry Maxwell

CFO

John Neis

Principal

Naofumi Nishi

Managing Director

Gordon G. Pan

President

James E. Pavlik

Partner, Technology Enabled Services

Samuel Pollard

Investment Associate

Summer Powers

Associate

John Reim

Associate

Benedict Rocchio

Partner

Chase Sanders

Managing Director, Technology and Services Group

Becca Schlagenhauf

Principal

David Schroeder

Operating Partner

Nick Sealy

Managing Director

Jeffrey Simmons

Managing Director

Steve Stahlberg

Managing Director and Regional Director

Bill Suddath

Managing Director and Co-Head, Global Healthcare Investment Banking

Andrew Szyman

Senior Associate

Jason Trennert

Chairman and CEO At Strategas

Andy Tse

Partner

Brett Tucker

Partner

David Ulbricht

Managing Director

Ross Wright

Associate

Milord Yip

Vice President

Yongshan (Samuel) Zhang

Principal, China Growth Equity

Jason Zhao

Venture Partner

Anthony Zhu

Principal

Matthias Zillmer

Partner

Past deals in Nebraska

Virtual Incision

Series C in 2021
Virtual Incision is the pioneer of in vivo mini-robot surgery, enabling minimally-invasive colon resection and other abdominal procedures. Colorectal cancer is the second-deadliest form of the disease, and along with conditions like Diverticulitis and Crohn’s, treatment often requires a colectomy, almost 400,000 of which are performed each year in the U.S. alone. Two-thirds of these procedures are still performed open, requiring a long, gruesome incision. VIC’s simpler/easier/cheaper approach is to insert a mini-robot into the insufflated abdomen via a small umbilical incision, after which the highly-dextrous robot arms are freely manipulated at the nearby surgeon console. VIC enables MIS colectomy using well-known laparoscopic tools, onboard vision, and leading multi-quadrant capabilities. After 70+ pig labs and with 60+ patents/applications, VIC is seeking a $15M Series B financing to achieve First-in-Man and prepare for CE Mark and FDA 510(k) submissions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.